Abstract:Alport syndrome is a hereditary kidney disease characterized by progressive renal failure especially for patients with autosomal recessive and X-linked inheritance.1Kashtan C.E. Alport syndrome: achieving early diagnosis and treatment.Am J Kidney Dis. 2021; 77: 272-279https://doi.org/10.1053/j.ajkd.2020.03.026Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar At present, no preventive or curative therapies are available. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Though the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial suggests a beneficial effect of SGLT2 inhibitors (SGLT2i) in chronic kidney disease of nonmetabolic origin,3Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.Dapagliflozin in patients with chronic kidney disease.N Engl J Med. 2020; 383: 1436-1446https://doi.org/10.1056/NEJMoa2024816Crossref PubMed Scopus (1125) Google Scholar whether a conclusion can be extrapolated for the treatment of rapidly progressive genetic kidney disease is unknown.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Therefore, we explored the efficacy and safety of SGLT2i in adult autosomal recessive Alport syndrome.This was a real-world study based on our dynamic cohort of Alport syndrome (Supplementary Methods and Supplementary Table S1 Supplementary Table S1). With a follow-up of 4 to 6 months, proteinuria showed a decreasing trend in all the 3 cases of autosomal recessive Alport syndrome, with 24-hour proteinuria decreasing by 0.17 g/24h (8.9%), 0.61 g/24h (39.9%), and 0.69 g/24h (52.3%) respectively (Figure 1). Urinary albumin-creatinine ratio decreased by 374.92 mg/g (26.9%), 561.03 mg/g (44.0%), and 234.33 mg/g (68.7%), respectively. Correspondingly, the serum albumin showed an increment on the whole. Importantly, the serum creatinine and estimated glomerular filtration rate remained stable. No patient discontinued dapagliflozin due to safety concerns and no clinically adverse effect was observed.In this report, the good efficacy of dapagliflozin is reported for the first time in patients with autosomal recessive Alport syndrome who presented with decreased renal function. Proteinuria decreased steadily after administration of dapagliflozin. No patient discontinued SGLT2i therapy due to safety concerns during the follow-up period of 6 months. Limitations should be acknowledged. First, the study included patients with mild or moderate proteinuria, rather than nephrotic proteinuria. Second, this is a pilot study, and more high quality studies with control samples are needed to verify our results.In conclusion, the pilot study showed good efficacy and tolerance of half-dose dapagliflozin in patients with Alport syndrome. Application of SGLT2i as an add-on therapy may be considered. A high quality study with a larger number of patients given full dose dapagliflozin is needed in the future.DisclosureAll the authors declared no conflict of interest. Alport syndrome is a hereditary kidney disease characterized by progressive renal failure especially for patients with autosomal recessive and X-linked inheritance.1Kashtan C.E. Alport syndrome: achieving early diagnosis and treatment.Am J Kidney Dis. 2021; 77: 272-279https://doi.org/10.1053/j.ajkd.2020.03.026Abstract Full Text Full Text PDF PubMed Scopus (25) Google Scholar At present, no preventive or curative therapies are available. Current treatment includes the use of renin-angiotensin-aldosterone system inhibitors which slow progression of kidney disease and prolong life expectancy.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Though the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial suggests a beneficial effect of SGLT2 inhibitors (SGLT2i) in chronic kidney disease of nonmetabolic origin,3Heerspink H.J.L. Stefánsson B.V. Correa-Rotter R. et al.Dapagliflozin in patients with chronic kidney disease.N Engl J Med. 2020; 383: 1436-1446https://doi.org/10.1056/NEJMoa2024816Crossref PubMed Scopus (1125) Google Scholar whether a conclusion can be extrapolated for the treatment of rapidly progressive genetic kidney disease is unknown.2Chavez E. Rodriguez J. Drexler Y. Fornoni A. Novel therapies for Alport syndrome.Front Med (Lausanne). 2022; 9848389https://doi.org/10.3389/fmed.2022.848389Crossref PubMed Scopus (2) Google Scholar Therefore, we explored the efficacy and safety of SGLT2i in adult autosomal recessive Alport syndrome. This was a real-world study based on our dynamic cohort of Alport syndrome (Supplementary Methods and Supplementary Table S1 Supplementary Table S1). With a follow-up of 4 to 6 months, proteinuria showed a decreasing trend in all the 3 cases of autosomal recessive Alport syndrome, with 24-hour proteinuria decreasing by 0.17 g/24h (8.9%), 0.61 g/24h (39.9%), and 0.69 g/24h (52.3%) respectively (Figure 1). Urinary albumin-creatinine ratio decreased by 374.92 mg/g (26.9%), 561.03 mg/g (44.0%), and 234.33 mg/g (68.7%), respectively. Correspondingly, the serum albumin showed an increment on the whole. Importantly, the serum creatinine and estimated glomerular filtration rate remained stable. No patient discontinued dapagliflozin due to safety concerns and no clinically adverse effect was observed. In this report, the good efficacy of dapagliflozin is reported for the first time in patients with autosomal recessive Alport syndrome who presented with decreased renal function. Proteinuria decreased steadily after administration of dapagliflozin. No patient discontinued SGLT2i therapy due to safety concerns during the follow-up period of 6 months. Limitations should be acknowledged. First, the study included patients with mild or moderate proteinuria, rather than nephrotic proteinuria. Second, this is a pilot study, and more high quality studies with control samples are needed to verify our results. In conclusion, the pilot study showed good efficacy and tolerance of half-dose dapagliflozin in patients with Alport syndrome. Application of SGLT2i as an add-on therapy may be considered. A high quality study with a larger number of patients given full dose dapagliflozin is needed in the future. DisclosureAll the authors declared no conflict of interest. All the authors declared no conflict of interest. Support was provided by National Science Foundation of China ( 82022010 ); Beijing Natural Science Foundation ( Z190023 ); Chinese Academy of Medical Sciences ( CAMS) Innovation Fund for Medical Sciences ( 2019-I2M-5-046 ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The data will be available on request. The patients have given consent for their clinical information to be published in the journal. Supplementary Material Download .pdf (.11 MB) Help with pdf files Supplementary File (PDF)Supplementary Methods.Table S1. Main effects of SGLT2 inhibitors (dapagliflozin 5 mg) in 3 adults with autosomal recessive Alport syndrome. Download .pdf (.11 MB) Help with pdf files Supplementary File (PDF) Supplementary Methods. Table S1. Main effects of SGLT2 inhibitors (dapagliflozin 5 mg) in 3 adults with autosomal recessive Alport syndrome.

Efficacy and Safety of Dapagliflozin in Children with Inherited Proteinuric Kidney Disease: A Pilot Study.

[Short-term efficacy of dapagliflozin in children with hereditary proteinuric kidney disease].

Efficacy and safety of dapagliflozin in children with kidney disease: real-world data

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Efficacy and safety of SGLT2 inhibitors in nondiabetic patients with CKD: a review of recent evidence

SGLT2 Inhibition: A New Glimmer of Hope to Slow Chronic Kidney Disease Progression in Children?

Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in pediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport

Renoprotection with Sodium-Glucose Cotransporter-2 Inhibitors in Children: Knowns and Unknowns.

Randomized Trial of SGLT2 Inhibitor Identifies Target Proteins in Diabetic Kidney Disease

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction

The Renoprotective Effects of SGLT2 Inhibitors versus Placebo in Patients with Type 2 Diabetes with or without Prevalent Kidney Disease: A Systematic Review and Meta-analysis.

Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy

Efficacy of Dapagliflozin in Adult Autosomal Recessive Alport Syndrome

Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b

385-P: Effects of Ertugliflozin on Podocyte in High-Fat Diet–Induced Diabetic Kidney Disease Model, In Vivo and In Vitro

Renal outcomes with sodium glucose cotransporter 2 (SGLT2) inhibitor, dapagliflozin, in obese insulin-resistant model

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis

The SGLT2 inhibitor dapagliflozin improves kidney function in glycogen storage disease XI

Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function